Real-World Study of Everolimus in Advanced Progressive Neuroendocrine TumorsFrancesco Panzuto, Gianfranco Delle Fave, Marco Merlano et al.|The Oncologist|2014Cited by 103
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine TumorGiuseppe Lamberti, Davide Campana, Antongiulio Faggiano et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 41
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizationsFrancesco Panzuto, Davide Campana, Sara Pusceddu et al.|Pancreatology|2019Cited by 27
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Massimo Falconi, Stefano Partelli et al.|Endocrine|2024Cited by 19
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine TumorsFrancesco Panzuto, Gianfranco Delle Fave, Maria Rinzivillo et al.|The Oncologist|2015Cited by 9